Asahi Life Asset Management CO. LTD. Grows Holdings in Pfizer Inc. (NYSE:PFE)

Asahi Life Asset Management CO. LTD. grew its holdings in Pfizer Inc. (NYSE:PFEGet Rating) by 1.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 19,540 shares of the biopharmaceutical company’s stock after purchasing an additional 360 shares during the period. Asahi Life Asset Management CO. LTD.’s holdings in Pfizer were worth $855,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. RB Capital Management LLC increased its stake in shares of Pfizer by 6.7% during the first quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock valued at $282,000 after buying an additional 341 shares during the period. Ironwood Wealth Management LLC. increased its stake in shares of Pfizer by 1.1% during the first quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock valued at $1,868,000 after buying an additional 400 shares during the period. United Bank increased its stake in shares of Pfizer by 0.6% during the first quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock valued at $2,416,000 after buying an additional 290 shares during the period. Ergoteles LLC increased its stake in shares of Pfizer by 136.3% during the first quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock valued at $1,903,000 after buying an additional 21,209 shares during the period. Finally, Mackenzie Financial Corp increased its stake in shares of Pfizer by 6.4% during the first quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock valued at $69,238,000 after buying an additional 79,887 shares during the period. Hedge funds and other institutional investors own 67.62% of the company’s stock.

Pfizer Stock Up 0.2 %

NYSE PFE traded up $0.08 during trading on Wednesday, hitting $44.79. The company’s stock had a trading volume of 2,681,125 shares, compared to its average volume of 23,014,340. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.59 and a quick ratio of 1.37. The company has a market cap of $251.42 billion, a PE ratio of 8.60, a P/E/G ratio of 1.11 and a beta of 0.67. The business’s 50 day simple moving average is $49.68 and its 200-day simple moving average is $48.06. Pfizer Inc. has a fifty-two week low of $41.44 and a fifty-two week high of $56.32.

Pfizer (NYSE:PFEGet Rating) last issued its quarterly earnings results on Tuesday, November 1st. The biopharmaceutical company reported $1.78 earnings per share for the quarter, topping the consensus estimate of $1.47 by $0.31. The business had revenue of $22.64 billion during the quarter, compared to the consensus estimate of $21.04 billion. Pfizer had a return on equity of 43.95% and a net margin of 29.81%. On average, equities analysts anticipate that Pfizer Inc. will post 6.47 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 3rd. Investors of record on Friday, January 27th will be issued a dividend of $0.41 per share. This is an increase from Pfizer’s previous quarterly dividend of $0.40. The ex-dividend date is Thursday, January 26th. This represents a $1.64 dividend on an annualized basis and a dividend yield of 3.66%. Pfizer’s payout ratio is 30.77%.

Analyst Ratings Changes

Several brokerages have recently commented on PFE. UBS Group set a $55.00 price target on Pfizer in a research note on Wednesday, January 18th. StockNews.com began coverage on Pfizer in a research note on Wednesday, October 12th. They set a “strong-buy” rating on the stock. Barclays raised their price target on Pfizer from $44.00 to $49.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 2nd. JPMorgan Chase & Co. set a $50.00 target price on Pfizer in a research note on Wednesday, January 18th. Finally, Wells Fargo & Company lowered Pfizer from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $54.00 to $50.00 in a research note on Tuesday, January 17th. Seven research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $53.00.

Pfizer Profile

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Featured Articles

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEGet Rating).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.